The latest cause of financial angst in biotech is FIN 46, the new accounting rule that could force drug companies to consolidate the expenses of their biotech partners, whether they own significant equity stakes or not. What will this affect? How about: any joint ventures, any co-development deals, and co-promotion, any R&D funding contracts-even, possibly, distribution and supply contracts.
One of the less obvious after-effects of the Enron debacle, note industry dealmakers and CFOs, has been the increasing reluctance of accountants to give clear answers. "They're more scared than we are" about issuing opinions, notes one head of business development.
And that's not what company executives want to hear during what Peter Wirth, Genzyme Corp. 's EVP and chief...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
